VALERIO THERAPEUTICS Paris (France), April 25, 2017 - 5.45 pm CET - Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), a biotechnology company specializing in the development of innovative drugs for the treatment of orphan diseases, in particular in oncology, today announced the publication of the Company's 2016 Registration Document.
The 2016 Registration Document, filed with the French Market Authorities (Autorité des Marchés Financiers) on April 24, 2017, is available to the public free of charge upon request, as per current legal regulations, at Onxeo's headquarters - 49 Boulevard du Général Martial Valin, 75015 Paris - and on the Company's website: http://www.onxeo.com/en/investisseurs/resultats-et-publications.
The annual financial report, the report of the Chairman of the Board of Directors on corporate governance and internal control and risk management procedures as well as the related auditors' reports and information on the fees paid to the statutory auditors in 2016 are included in this Registration Document.
170424_Onxeo_DDR_2016_ENG-vl
Onxeo SA published this content on 25 April 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 25 April 2017 17:32:02 UTC.
Original documenthttp://www.onxeo.com/en/publication-2016-registration-document/
Public permalinkhttp://www.publicnow.com/view/C245BC1ABE1D531351C0B09700EE5EB738D929D8
